1 / 8

David J. Whellan, MD, MHS Jefferson Medical College, Philadelphia, PA Christopher M. O’Connor, MD

O’Connor - 3318. Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized C ontrolled T rial I nvestigating O utcomes of Exercise Trai N ing (HF-ACTION). David J. Whellan, MD, MHS

tamah
Télécharger la présentation

David J. Whellan, MD, MHS Jefferson Medical College, Philadelphia, PA Christopher M. O’Connor, MD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. O’Connor - 3318 Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) David J. Whellan, MD, MHS Jefferson Medical College, Philadelphia, PA Christopher M. O’Connor, MD Duke University Medical Center, Durham, NC on behalf of the HF-ACTION Steering Committee, Investigators, and Coordinators Funded by NHLBI Ancillary studies funded by GE Healthcare and Roche Diagnostics Financial Disclosures: Research Support: GE Healthcare, Roche Diagnostics

  2. Background • In past studies, exercise training has • Increased exercise capacity • Improved quality of life • Improved biomarkers • Possibly improved survival • Limitations • Relatively small • Majority single-center • Underpowered to evaluate mortality and morbidity • Lack of adequate control groups • Limited safety data

  3. HF-ACTION Outcomes • All-cause mortality + hospitalization: Primary • CV mortality + CV hospitalization • CV mortality + HF hospitalization • Mortality • Safety • Physiologic endpoints: CPX and 6MW • QOL • Cost

  4. Study Design Chronic heart failure, NYHA Class II-IV, LVEF ≤ 35%, optimal medical therapy, and capable of exercising Pre-randomization CPX and ECHO Randomization 1:1 (Stratified by center and HF etiology) Usual Care Exercise Training Optimized medical treatment Patient education Phone calls Recommendation: Moderate intensity activity 30 minutes/day Optimized medical treatment Patient education Phone calls Supervised training Home training

  5. Time to All-Cause Mortality or All-Cause Hospitalization HR 0.93 (95% CI: 0.84, 1.02), P=0.13

  6. Summary of Major Outcomes

  7. Limitations • Adherence in exercise training group and physical activity by the usual care group may have diminished the identified benefit of exercise training • Blinding of subjects and research personnel not possible • Core labs blinded • Clinical Endpoint Committee blinded • Home exercise adherence data are difficult to collect and to precisely quantify

  8. Conclusions • The HF- ACTION Trial is the largest and most comprehensive study of exercise training in patients with heart failure. • Based on the protocol-specified primary analysis, exercise training produced a modest, non-significant decrease in the primary endpoint (all-cause mortality or all-cause hospitalization) and key secondary clinical endpoints. • In secondary analyses, with adjustment for the most significant, objectively-determined prognostic factors, the adjusted treatment effect was statistically significant for the primary endpoint and for the secondary endpoint of CV mortality or HF hospitalization. • The HF-ACTION study results support a structured exercise training program for patients with reduced LV function and HF symptoms in addition to evidence-based therapy.

More Related